Articles

Engineering Access: It All Comes Back to the Patient Experience

Advanced Therapies: Access Is Still the Hard Part

CAR-T Platform Moves Novel Therapies from Gene Sequence to Clinic-ready in Under 12 Months

CAR-T has a geography problem

The Next Cancer Revolution Isn’t Scientific—It’s Manufacturing

How are capital constraints impacting M&A and strategic partnerships in the CDMO and pharma sectors?

What economic or market trends are having the biggest impact on CDMO capacity and pipelines in 2025, and what will 2026 bring?

What do you see as the biggest threat to the CDMO industry in 2026 or beyond?

What do you consider to be the most important new tools or technology platforms currently being developed?

Vector BioMed Brings Affordable CAR-T Cell Therapies In India

Scroll to Top